Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506630 | 0.76 | EPHX1 (0.40) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL10905089 | 0.74 | SHBG (0.39) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL16236755 | 0.74 | EPHX1 (0.39) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL5736947 | 0.74 | SHBG (0.39) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL986069 | 0.74 | SHBG (0.39) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL5736515 | 0.74 | SHBG (0.39) | SHBGEPHX1TP53KDM4EGMNN | |
| SCHEMBL10901657 | 0.70 | SHBG (0.35) | SHBG | |
| SCHEMBL4654069 | 0.70 | SHBG (0.35) | SHBG | |
| SCHEMBL8849193 | 0.69 | SHBG (0.34) | SHBGEPHX1 | |
| SCHEMBL5074257 | 0.69 | SHBG (0.34) | SHBGEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680218-A2 | SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS | Promerus, LLC (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005042147-A2 | SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS | PROMERUS, LLC (US) | 2005-05-12 | — | — | WO | claimed |
| EP-1680218-A2 | SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS | Promerus, LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050187398-A1 | Single component cationic palladium proinitiators for the latent polymerization of cycloolefins | PROMERUS, LLC | 2005-08-25 | — | — | US | disclosed |
| WO-2005042147-A2 | SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS | PROMERUS, LLC (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187398-A1 | Single component cationic palladium proinitiators for the latent polymerization of cycloolefins | LRRK2, LBR, SNCA | SHBG 4581/4885EPHX1 3156/4885TP53 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.